Results 21 to 30 of about 38,785 (336)
Postgraduate Medical Journal, 1987 Acute mountain sickness (AMS) is a clinical syndrome occurring in otherwise healthy normal individuals who ascend rapidly to high altitude. Symptoms develop over a period ofa few hours or days. The usual symptoms include headache, anorexia, nausea, vomiting, lethargy, unsteadiness of gait, undue dyspnoea on moderate exertion and interrupted sleep.
A. D. Wright, R. F. Fletcher
openaire +3 more sources
Contribution of Hypoxic Exercise Testing to Predict High-Altitude Pathology: A Systematic Review
Life, 2022 Altitude travelers are exposed to high-altitude pathologies, which can be potentially serious. Individual susceptibility varies widely and this makes it difficult to predict who will develop these complications.
Thomas Georges +5 more
doaj +1 more source
Hereditas, 2020 Background Acute mountain sickness has become a heavily researched topic in recent years. However, the genetic mechanism and effects have not been elucidated. Our goal is to construct a gene co-expression network to identify the key modules and hub genes
Yue Chang +6 more
doaj +1 more source
Journal of Education, Health and Sport, 2020 The hypoxia is the main cause of altitude sickness, that usually starts from the benign form - acute mountain sickness (AMS), that being untreated can progress to the life-threatening states, like high altitude pulmonary edema (HAPE) and high altitude ...
Karol Mazur +4 more
doaj +1 more source
Prediction of acute mountain sickness [PDF]
BMJ, 1995 Acute mountain sickness is a common problem when ascending above 3000 m.1 2 3 Attempts to predict its development have so far been unsuccessful, and the side effects of current prophylaxis limit its widespread use. We tried to develop a simple clinical method of prediction.
AUSTIN, D, SLEIGH, J
openaire +3 more sources
Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial [PDF]
, 2013 BACKGROUND: Rhodiola crenulata (R. crenulata) is widely used to prevent acute mountain sickness in the Himalayan areas and in Tibet, but no scientific studies have previously examined its effectiveness.
Chung-Hsien Chen +6 more
core +1 more source
High Altitude Medicine & Biology, 2002 AFIT 57-YEAR-OLD MALE trekker/climber presented at Dingboche, Nepal (4420 m), with severely limited exercise tolerance (it was an effort for him to walk from his room to the dining area), headache, and nausea. These symptoms first appeared 2 days earlier when he returned to Lobouche (5029 m) after climbing Kalapatar (5600 m).
Taylor, A +10 more
openaire +4 more sources
Inhaled Budesonide and Oral Dexamethasone Prevent Acute Mountain Sickness [PDF]
, 2014 BackgroundThis double-blind, randomized controlled trial aimed to investigate inhaled budesonide and oral dexamethasone compared with placebo for their prophylactic efficacy against acute mountain sickness after acute high-altitude exposure.MethodsThere ...
Bian, Shi-Zhu +11 more
core +1 more source
Effects of age on hypoxic tolerance in women
Current Issues in Sport Science, 2023 Introduction The prevalence of acute mountain sickness (AMS) is increasing with altitude (i.e., 10-25% at 2,500 m and 50-85% at ~ 5,000 m; Bärtsch & Swenson, 2013). While there is no error-free test to predict its occurrence, several risk factors and
Tom Citherlet +3 more
doaj +1 more source
Does This Patient Have Acute Mountain Sickness?: The Rational Clinical Examination Systematic Review. [PDF]
, 2017 Acute mountain sickness (AMS) affects more than 25% of individuals ascending to 3500 m (11 500 ft) and more than 50% of those above 6000 m (19 700 ft).
Collet, T.H. +6 more
core +2 more sources